SAFETY DATA SHEETS

This SDS packet was issued with item:

078941225

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078941224

SAFETY DATA SHEET



1. Identification

Product identifier Danofloxacin mesylate injectable solution

Other means of identification

Synonyms ADVOCID™ * ADVOCIN™ * A180® * A180® Sterile Injectable Solution * Advocid 180 * Advocin

180 * ADVOCIN Sterile Injectable Solution * Advocin Injectable Solution

Recommended useVeterinary product used as antibiotic agent

Recommended restrictions Not for human use

Manufacturer/Importer/Supplier/Distributor information

Company Name (US) Zoetis Inc.

10 Sylvan Way

Parsippany, New Jersey 07054 (USA)

Rocky Mountain Poison

and Drug Center

1-866-531-8896

Product Support/Technical

Services

1-800-366-5288

Emergency telephone

numbers

CHEMTREC (24 hours): 1-800-424-9300

International CHEMTREC (24 hours): +1-703-527-3887

Company Name (EU) Zoetis Belgium S.A.

Mercuriusstraat 20 1930 Zaventem

Belgium

Emergency telephone

number

International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail VMIPSrecords@zoetis.com

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Specific target organ toxicity, repeated

Category 2 (connective tissue, reproductive system, heart, kidney, nervous system)

exposure system, heart, kidney, nervou

Environmental hazards Hazardous to the aquatic environment, acute

hazard

Hazardous to the aquatic environment,

Category 3

Category 3

long-term hazard

OSHA defined hazards Not classified.

Label elements



Signal word Warning

Hazard statement May cause damage to organs (connective tissue, reproductive system, heart, kidney, nervous

system) through prolonged or repeated exposure. Harmful to aquatic life with long lasting effects.

Precautionary statement

Prevention Do not breathe mist or vapor. Avoid release to the environment.

Response Get medical advice/attention if you feel unwell.

Storage Store away from incompatible materials.

Disposal Dispose of contents/container in accordance with local/regional/national/international regulations.

Hazard(s) not otherwise

classified (HNOC)

Material name: Danofloxacin mesylate injectable solution

183 Version #: 03 Revision date: 05-31-2017 Issue date: 11-25-2013

None known.

SDS US

Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Drugs of this class have been associated with rare, but potentially serious cardiac events. These effects have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
2-Pyrrolidone		616-45-5	20
Danofloxacin mesylate		119478-55-6	18
Magnesium oxide		1309-48-4	2.03
Phenol		108-95-2	<1

Composition comments

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. First-aid measures

Inhalation

Move to fresh air. If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician. For breathing difficulties, oxygen may be necessary.

Skin contact

Wash off immediately with soap and plenty of water. If skin irritation or rash occurs: Get medical advice/attention. Wash contaminated clothing before reuse. There is a risk of photosensitization within a few hours after excessive exposure to quinolones. If excessive exposure does occur, avoid direct sunlight and wash skin with soap and water.

Eye contact

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. Remove contact lenses, if present and easy to do.

Ingestion

Rinse mouth. Call a physician or poison control center immediately. Do not induce vomiting without advice from poison control center. Never give anything by mouth to a victim who is unconscious or is having convulsions.

Most important symptoms/effects, acute and delayed

Direct contact with eyes may cause temporary irritation. Exposed individuals may experience eye tearing, redness, and discomfort. Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. Rash. (allergic skin rash); Difficulty in breathing. Quinolones may effect connective tissue structures. Tendonitis and tendon rupture have occurred as late as several months after quinolone treatment. Convulsions, increased intracranial pressure, and toxic psychosis have been reported in patients receiving quinolones. The most common adverse reactions associated with the use of quinolones include gastrointestinal distress, such as nausea or diarrhea, and central nervous system (CNS) effects, including insomnia, dizziness, and seizures. sensory/motor nerve injury (peripheral neuropathy) may occur.

Indication of immediate medical attention and special treatment needed

May cause central nervous system effects. Individuals with cardiac conditions may be more susceptible to toxicity in cases of overexposure. Monitor respiratory, cardiac and central nervous system. Provide general supportive measures and treat symptomatically. Keep victim under observation. Symptoms may be delayed.

General information

IF exposed or concerned: Get medical advice/attention. For personal protection, see section 8 of the SDS. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Show this safety data sheet to the doctor in attendance. CAUTION! - Individuals with a history of hypersensitivity to this material or members of the quinolone class of antimicrobials and those with known seizure disorders. Individuals with cardiac conditions may be more susceptible to toxicity in cases of overexposure.

5. Fire-fighting measures

Suitable extinguishing media Unsuitable extinguishing media Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2). Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting equipment/instructions

Move containers from fire area if you can do so without risk.

Specific methods
General fire hazards

Use standard firefighting procedures and consider the hazards of other involved materials.

No unusual fire or explosion hazards noted.

Material name: Danofloxacin mesylate injectable solution

SDS US

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures Keep unnecessary personnel away. Ensure adequate ventilation. Wear appropriate protective equipment and clothing during clean-up. Do not breathe mist or vapor. Avoid contact with eyes, skin, and clothing. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8 of the SDS.

Methods and materials for containment and cleaning up

Ensure adequate ventilation. Prevent product from entering drains.

Large Spills: Stop the flow of material, if this is without risk. Absorb in vermiculite, dry sand or earth and place into containers. Following product recovery, flush area with water.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Environmental precautions

Never return spills to original containers for re-use. For waste disposal, see section 13 of the SDS. Avoid release to the environment. Inform appropriate managerial or supervisory personnel of all environmental releases. Prevent further leakage or spillage if safe to do so. Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Wear appropriate personal protective equipment. Do not handle, store or open near an open flame, sources of heat or sources of ignition. Protect material from direct sunlight. Avoid breathing mist or vapor. Avoid contact with eyes, skin, and clothing. Avoid accidental injection. Avoid prolonged exposure. Observe good industrial hygiene practices. When using, do not eat, drink or smoke. Wash thoroughly after handling. Avoid release to the environment.

Conditions for safe storage, including any incompatibilities

Store in a well-ventilated place. $@ \le 30\text{C/86F}$. Store in a tightly closed container. Protect from light. Protect from sunlight. Keep away from heat, sparks and open flame. Do not allow material to freeze. Store away from incompatible materials (see Section 10 of the SDS). Keep out of the reach of children.

8. Exposure controls/personal protection

Occupational exposure limits

The following constituents are the only constituents of the product which have a PEL, TLV or other recommended exposure limit. At this time, the other constituents have no known exposure limits.

Zoetis Components	Туре	Value	
Danofloxacin mesylate (CAS 119478-55-6)	TWA	200 μg/m3	
US. OSHA Table Z-1 Limits for Air	Conteminants (20 CER 1010 1	000)	
Components	Type	Value Value	Form
Magnesium oxide (CAS 1309-48-4)	PEL	15 mg/m3	Total particulate.
Phenol (CAS 108-95-2)	PEL	19 mg/m3	
		5 ppm	
US. OSHA Table Z-3 (29 CFR 1910	.1000)		
Components	Туре	Value	Form
Magnesium oxide (CAS 1309-48-4)	TWA	5 mg/m3	Respirable fraction.
,		15 mg/m3	Total dust.
		50 mppcf	Total dust.
		15 mppcf	Respirable fraction.
US. ACGIH Threshold Limit Values	S		
Components	Туре	Value	Form
Magnesium oxide (CAS 1309-48-4)	TWA	10 mg/m3	Inhalable fraction.
Phenol (CAS 108-95-2)	TWA	5 ppm	
US. NIOSH: Pocket Guide to Chem	nical Hazards		
Components	Туре	Value	
Phenol (CAS 108-95-2)	Ceiling	60 mg/m3	
•	•	15.6 ppm	

Material name: Danofloxacin mesylate injectable solution

 Components
 Type
 Value

 TWA
 19 mg/m3

19 mg/m3 5 ppm

Biological limit values

ACGIH Biological Exposure Indices

Components	Value	Determinant	Specimen	Sampling Time
Phenol (CAS 108-95-2)	250 mg/g	Phenol with hydrolysis	Creatinine in urine	*

^{* -} For sampling details, please see the source document.

Exposure guidelines

US - California OELs: Skin designation

Phenol (CAS 108-95-2) Can be absorbed through the skin.

US - Minnesota Haz Subs: Skin designation applies

Phenol (CAS 108-95-2) Skin designation applies.

US - Tennessee OELs: Skin designation

Phenol (CAS 108-95-2) Can be absorbed through the skin.

US ACGIH Threshold Limit Values: Skin designation

Phenol (CAS 108-95-2) Can be absorbed through the skin.

US NIOSH Pocket Guide to Chemical Hazards: Skin designation

Phenol (CAS 108-95-2)

Can be absorbed through the skin.

US. OSHA Table Z-1 Limits for Air Contaminants (29 CFR 1910.1000)

Not available.

Phenol (CAS 108-95-2) Can be absorbed through the skin.

Control banding approach

Appropriate engineering

controls

Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. General room ventilation is adequate unless the process generates dust, mist or aerosols.

Individual protection measures, such as personal protective equipment

Eye/face protection If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection Wear appropriate chemical resistant gloves. Impervious gloves are recommended if skin contact

with drug product is possible and for bulk processing operations.

Other Wear suitable protective clothing. Use protective clothing (uniforms, lab coats, disposable

coveralls, etc.) in both production and laboratory areas.

Respiratory protection No personal respiratory protective equipment normally required. In case of insufficient ventilation,

wear suitable respiratory equipment. Whenever air contamination (mist, vapor or odor) is generated, respiratory protection is recommended as a precaution to minimize exposure. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a

protection factor sufficient to control exposures to below the OEL.

Thermal hazards Not applicable.

General hygieneConsiderations
Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective

equipment to remove contaminants.

9. Physical and chemical properties

Appearance Sterile solution.

Physical state Liquid.
Form Liquid.
Color Colorless.
Odor Not available.
Odor threshold Not available.

pH 7.5

Melting point/freezing point Not available.

Initial boiling point and boiling

range

Not available.

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not applicable.

Upper/lower flammability or explosive limits

Flammability limit - lower

(%)

Not available.

Flammability limit - upper

(%)

Not available.

Explosive limit - lower (%) Not available.

Explosive limit - upper (%) Not available.

Not available.

Vapor pressureNot available.Vapor densityNot available.Relative densityNot available.

Solubility(ies)

Solubility (water) Soluble

Partition coefficient Not available. (n-octanol/water)

Auto-ignition temperature Not available.

Decomposition temperature Not available.

Viscosity Not available.

Other information

Explosive propertiesNot explosive. **Oxidizing properties**Not oxidizing.

10. Stability and reactivity

ReactivityThe product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials. Heat, flames and sparks. Exposure to light. Sunlight. Protect

from freezing.

Incompatible materials Peroxides. Phenols. Strong oxidizing substances.

Hazardous decomposition

Danofloxacin mesylate

products

Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

11. Toxicological information

Information on likely routes of exposure

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

May cause hypersensitivity reactions in susceptible individuals.

Skin contact Prolonged skin contact may cause temporary irritation. May cause hypersensitivity reactions in

susceptible individuals. Photosensitivity may occur.

Danofloxacin mesylate Species: Rabbit

Severity: Mild

Phenol Species: Rabbit

Severity: Severe

Eye contact Direct contact with eyes may cause temporary irritation.

Species: Rabbit Severity: No effect

Phenol Species: Rabbit

Severity: Severe

Material name: Danofloxacin mesylate injectable solution

SDS US

Ingestion

Ingestion may result in mild gastrointestinal irritation with nausea, vomiting, or diarrhea. However, ingestion is not likely to be a primary route of occupational exposure.

Symptoms related to the physical, chemical and toxicological characteristics Direct contact with eyes may cause temporary irritation. Exposure may cause temporary irritation, redness, or discomfort. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Rash. (allergic skin rash); Difficulty in breathing. Quinolones may effect connective tissue structures. Tendonitis and tendon rupture have occurred as late as several months after quinolone treatment. Convulsions, increased intracranial pressure, and toxic psychosis have been reported in patients receiving quinolones. The most common adverse reactions associated with the use of quinolones include gastrointestinal distress, such as nausea or diarrhea, and central nervous system (CNS) effects, including insomnia, dizziness, and seizures. sensory/motor nerve injury (peripheral neuropathy) may occur.

Information on toxicological	effects	
Acute toxicity	Ingestion may result in mild gast	trointestinal irritation with nausea, vomiting, or diarrhea.
Product	Species	Test Results
Danofloxacin mesylate injectat	ple solution	
<u>Acute</u>		
Dermal		
LD50	Rat	> 5000 mg/kg (ATE)
Inhalation		
LC50	Rat	> 10 mg/l (ATE)
Oral		
LD50	Rat	> 5000 mg/kg (ATE)
Components	Species	Test Results
Danofloxacin mesylate (CAS 1	19478-55-6)	
<u>Acute</u>		
Intravenous		
LD50	Mouse	50 - 100 mg/kg
	Rat	100 - 150 mg/kg
Oral		
LD50	Mouse	> 2000 mg/kg
	Rat	> 2000 mg/kg
<u>Chronic</u>		
Oral		
LOEL	Rat	10 mg/L/day, 2 years [Effect(s): Tumors, Female reproductive system (Female rat)]
		10 mg/kg/day, 2 years [Target organ(s): Kidney, Male reproductive system]
<u>Subchronic</u>		
Oral		
LOEL	Rat	25 mg/kg/day, 3 months [Target organ(s): Kidney, Heart, Male reproductive system]
NOEL	Dog	2.4 mg/kg/day, 90 days [Target organ(s): Skeletal muscle]
Phenol (CAS 108-95-2)		
<u>Acute</u>		
Dermal		
LD50	Rat	669 mg/kg
Inhalation		
LC50	Rat	316 mg/m3
Oral		
LD50	Rat	317 mg/kg
Skin corrosion/irritation	Prolonged skin contact may cau	se temporary irritation.

Corrosivity

Danofloxacin mesylate Species: Rabbit

Severity: MIId

Serious eye damage/eye

irritation

Direct contact with eyes may cause temporary irritation.

Eve Contact

Danofloxacin mesylate

Species: Rabbit

Severity: No effect

Species: Rabbit Severity: Severe

Respiratory or skin sensitization

Phenol

Due to partial or complete lack of data the classification is not possible. Individuals sensitive to Respiratory sensitization

this material or other materials in its chemical class may develop allergic reactions.

Due to partial or complete lack of data the classification is not possible. Individuals sensitive to this Skin sensitization

> material or other materials in its chemical class may develop allergic reactions. Skin sensitization and/or photosensitization potential (allergic response after UV exposure) of other quinolones have

been demonstrated in guinea pigs, mice, and humans.

No data available to indicate product or any components present at greater than 0.1% are Germ cell mutagenicity

mutagenic or genotoxic.

Mutagenicity

Danofloxacin mesylate Bacterial Mutagenicity (Ames)

Result: Negative Species: Salmonella

In Vitro Cytogenetics Result: Negative

Species: Human Lymphocytes

In Vivo Cytogenetics Result: Negative

Species: Mouse Bone Marrow

Mammalian Cell Mutagenicity

Result: Negative

Species: Mouse Lymphoma

Unscheduled DNA Synthesis

Result: Negative

Species: Rat Hepatocyte

Carcinogenicity

This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA.

IARC Monographs. Overall Evaluation of Carcinogenicity

Phenol (CAS 108-95-2)

3 Not classifiable as to carcinogenicity to humans.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not regulated.

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Reproductive toxicity

Due to partial or complete lack of data the classification is not possible. Repeat-dose studies in animals have shown a potential to cause adverse effects on testes. Possible risk of impaired fertility. Classification not possible. No evidence of teratogenicity or embryotoxicity was observed

for danofloxacin in mice, rats, or rabbits.

Developmental effects

Danofloxacin mesylate 100 mg/kg/day Embryo / Fetal Development, Not Teratogenic

Result: NOEL Species: Mouse Organ: Oral

Material name: Danofloxacin mesylate injectable solution

7 / 10 183 Version #: 03 Revision date: 05-31-2017 Issue date: 11-25-2013

Developmental effects

Danofloxacin mesylate 50 mg/kg/day Embryo / Fetal Development, Not Teratogenic

Result: NOEL Species: Rat Organ: Oral

Reproductivity

Danofloxacin mesylate 6.25 mg/kg/day Reproductive & Fertility, Fertility

Result: NOEL Species: Rat Organ: Oral

Specific target organ toxicity single exposure

Not classified.

Not an aspiration hazard.

May cause damage to organs (connective tissue, reproductive system, heart, kidney, nervous

Specific target organ toxicity repeated exposure

system) through prolonged or repeated exposure.

Aspiration hazard Further information

Possible risks of irreversible effects. sensory/motor nerve injury (peripheral neuropathy) may occur. This compound may cause cartilage deterioration in knee joints. Quinolones may effect connective tissue structures. Tendonitis and tendon rupture have occurred as late as several months after quinolone treatment. Drugs of this class have been associated with rare, but potentially serious cardiac events. These effects have not been observed from occupational exposures, however, those with preexisting cadiovascular illnesses may be at increased risk from

exposure.

12. Ecological information

Harmful to aquatic life with long lasting effects. Avoid release to the environment. **Ecotoxicity**

Components		Species	Test Results
2-Pyrrolidone (CAS 616-45-	5)		
	LC50	Daphnia magna (Water Flea)	13.21 mg/L, 48 Hours
Aquatic			
Crustacea	EC50	Water flea (Daphnia pulex)	13.21 mg/l, 48 hours
Danofloxacin mesylate (CAS	S 119478-55-6)		
	IC50	Champia	2.7 mg/L, 168 Hours
		Polytox	0.92 mg/L
	LC50	Cyprinodon variegatus (Sheepshead Minnow)	> 100 mg/L, 48 Hours
		Daphnia magna (Water Flea)	63.5 mg/L, 48 Hours
		Mysidopsis bahia (Mysid Shrimp)	> 100 mg/L, 48 Hours
Phenol (CAS 108-95-2)			
Aquatic			
Crustacea	EC50	Water flea (Daphnia obtusa)	4.7 - 6.4 mg/l, 48 hours
Fish	LC50	Asiatic knifefish (Notopterus notopterus)	8 - 8.25 mg/l, 96 hours
	No doto io ov	cilable on the degradability of this product	

Persistence and degradability

No data is available on the degradability of this product.

Bioaccumulative potential Mobility in soil

No data available. No data available.

Other adverse effects

No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Disposal instructions

Avoid release to the environment. Do not discharge into drains, water courses or onto the ground. Do not contaminate ponds, waterways or ditches with chemical or used container. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. Dispose of contents/container in accordance with local/regional/national/international regulations.

Local disposal regulations Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to

Not established.

Annex II of MARPOL 73/78 and the IBC Code

15. Regulatory information

US federal regulations This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication

Standard, 29 CFR 1910.1200.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Phenol (CAS 108-95-2) Listed.

SARA 304 Emergency release notification

Phenol (CAS 108-95-2) 1000 LBS

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not regulated

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - No

Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance

CAS number **Chemical name** Reportable **Threshold** Threshold **Threshold** quantity planning quantity planning quantity, planning quantity, (pounds) (pounds) lower value upper value (pounds) (pounds) Phenol 108-95-2 1000 10000 500

SARA 311/312 Hazardous No

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Phenol (CAS 108-95-2)

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act Not regulated.

(SDWA)

FEMA Priority Substances Respiratory Health and Safety in the Flavor Manufacturing Workplace

Phenol (CAS 108-95-2) Low priority

US state regulationsCalifornia Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

US. California. Candidate Chemicals List. Safer Consumer Products Regulations (Cal. Code Regs, tit. 22, 69502.3, subd. (a))

Magnesium oxide (CAS 1309-48-4)

Phenol (CAS 108-95-2)

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

 Issue date
 11-25-2013

 Revision date
 05-31-2017

Version # 03

United States & Puerto Rico

List of abbreviations ATE: Acute Toxicity Estimate according to REGULATION (EC) No 1272/2008 (CLP).

Toxic Substances Control Act (TSCA) Inventory

Disclaimer Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while

it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. The information in the sheet was written based on the best knowledge and experience currently

available.

Revision information This document has undergone significant changes and should be reviewed in its entirety.

Material name: Danofloxacin mesylate injectable solution

No